The global oral solid dosage contract manufacturing market is becoming an increasingly important part of the pharmaceutical manufacturing ecosystem as drug developers and pharmaceutical companies turn to specialized contract development and manufacturing organizations (CDMOs) for formulation development, scale-up, and commercial production. Rising outsourcing activity, growing generic drug...

The global oral solid dosage (OSD) contract manufacturing market was valued at USD 10.2 billion in 2025 and is projected to increase from USD 11.1 billion in 2026 to USD 21.3 billion by 2033, registering a compound annual growth rate (CAGR) of 9.7% from 2026 to 2033. North America accounted for the largest regional revenue share at 38.7% in 2025, while Asia Pacific is expected to experience the...